WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462576
CAS#: 2093565-23-0
Description: B7183 is a YAP/TAZ inhibitor.
Hodoodo Cat#: H462576
Name: B7183
CAS#: 2093565-23-0
Chemical Formula: C33H39N3O5S2
Exact Mass: 621.23
Molecular Weight: 621.811
Elemental Analysis: Chemical Formula: C33H39N3O5S2 Exact Mass: 621.2331 Molecular Weight: 621.8110 Elemental Analysis: C, 63.74; H, 6.32; N, 6.76; O, 12.86; S, 10.31
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: B7183; B 7183; B-7183; YAP/TAZ inhibitor-1; YAP/TAZ-IN-1;
IUPAC/Chemical Name: (E)-2-((4,4-dimethylcyclohexyl)sulfonyl)-7-((4-(1-phenylethyl)piperazin-1-yl)sulfonyl)-9H-fluoren-9-one oxime
InChi Key: MYVLNSCWZUAUMQ-NWBJSICCSA-N
InChi Code: InChI=1S/C33H39N3O5S2/c1-23(24-7-5-4-6-8-24)35-17-19-36(20-18-35)43(40,41)27-10-12-29-28-11-9-26(21-30(28)32(34-37)31(29)22-27)42(38,39)25-13-15-33(2,3)16-14-25/h4-12,21-23,25,37H,13-20H2,1-3H3/b34-32+
SMILES Code: O=S(C1=CC2=C(C=C1)C3=C(C=C(S(=O)(C4CCC(C)(C)CC4)=O)C=C3)/C2=N\O)(N5CCN(C(C6=CC=CC=C6)C)CC5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 621.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Patel S, Tang J, Overstreet JM, Anorga S, Lian F, Arnouk A, Goldschmeding R, Higgins PJ, Samarakoon R. Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. FASEB J. 2019 Sep;33(9):9797-9810. doi: 10.1096/fj.201802489RR. Epub 2019 May 16. PMID: 31095421; PMCID: PMC6704447.
2: Zmajkovicova K, Menyhart K, Bauer Y, Studer R, Renault B, Schnoebelen M, Bolinger M, Nayler O, Gatfield J. The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ. Am J Respir Cell Mol Biol. 2019 May;60(5):578-591. doi: 10.1165/rcmb.2018-0142OC. PMID: 30537446.
3: Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vrbanac V, Probst CK, Hiemer SE, Sisson TH, Horowitz JC, Rosas IO, Fredenburgh LE, Feghali-Bostwick C, Varelas X, Tager AM, Tschumperlin DJ. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57. doi: 10.1152/ajplung.00300.2014. Epub 2014 Dec 12. PMID: 25502501; PMCID: PMC4329470.
4: Thomasy SM, Morgan JT, Wood JA, Murphy CJ, Russell P. Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells. Exp Eye Res. 2013 Aug;113:66-73. doi: 10.1016/j.exer.2013.05.014. Epub 2013 May 29. PMID: 23727052; PMCID: PMC3737383.
